Compound Disease Phase
Rodatristat ethyl Pulmonary Arterial Hypertension (PAH) Phase 2
Idiopathic Pulmonary Fibrosis (IPF) Research
Sarcoidosis Research
ALTA-2530 Bronchiolitis Obliterans Syndrome IND Enabling
Next-Generation TPH Inhibitors Oral agents for multiple indications Research
Alternative routes of administration for multiple indications Research
CompoundDiseaseResearchIND EnablingPhase 1Phase 2Phase 3
Rodatristat Ethyl Pulmonary Arterial Hypertension (PAH)

PAH STUDY NOW ENROLLING
Click to Learn More

Idiopathic Pulmonary Fibrosis (IPF)
ALTA-2530 Transplant-associated bronchiolitis obliterans syndrome
Chemical-induced bronchiolitis obliterans syndrome

* Partnered with BARDA / NIAID

Next-Generation TPH Inhibitors Oral agents for multiple indications
Alternative routes of administration of multiple indications